Caramaschi P, Biasi D, Tonolli E, Carletto A, Bambara LM. Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature.
Joint Bone Spine 2002;
69:177-80. [PMID:
12027309 DOI:
10.1016/s1297-319x(02)00367-6]
[Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
OBJECTIVE
To evaluate the incidence, the subspecificities and the clinical correlation of antineutrophil cytoplasmic antibodies in scleroderma patients.
METHODS
Sixty-two patients affected by scleroderma in limited or diffuse pattern have been screened for the presence of anti-proteinase 3 and anti-myeloperoxidase antibodies by ELISA method.
RESULTS
Two patients affected by diffuse systemic sclerosis were found to be antineutrophil cytoplasmic antibody-positive. One patient presented a weak positivity for anti-myeloperoxidase antibodies in the absence of renal impairment. One patient which clinical course is characterised by rapidly progressive skin and lung involvement presented a high positivity for anti-proteinase 3 antibody.
CONCLUSION
Our study confirms the low incidence of antineutrophil cytoplasmic antibodies in scleroderma patients (3.2%); we reportthe first case of isolated scleroderma with positivity of anti-proteinase 3 antibodies.
Collapse